Neurology News

NeuroPace Inc. announced that the first patient with Lennox-Gastaut Syndrome was treated in its investigational device exemption feasibility study, which will evaluate the company’s neuromodulation technology.

Dementia prevalence dropped 3.7 percentage points in the U.S. from 2000 to 2016, according to a RAND Corporation study published in Proceedings of the National Academy of Sciences.

Clinical-stage biopharmaceutical company Clene Inc. announced proof-of-concept evidence of potential neuroprotective effects of CNM-Au8, an oral therapeutic for patients with stable relapsing-remitting MS.

The Parkinson’s Foundation and data analytics platform Tag.bio have announced a partnership to advance research into the causes and treatment of Parkinson’s disease.

Childhood poverty was associated with increases in externalizing problems, but not internalizing, over time in early adolescence, researchers reported in JAMA Network Open.

In this edition, risk factors linked to PD, digital brain health platform offers dementia risk assessment, Klotho protein levels linked to Alzheimer's and more.

Lecanemab reduced amyloid markers and slowed cognitive decline in patients with early Alzheimer’s disease, although not without risk for adverse events, according to new data published in The New England Journal of Medicine.

Biotechnology company Cajal Neuroscience announced its launch with $96 million Series A financing with plans to combine human genetics, functional genomics and advanced microscopy to expand drug discovery for neurodegenerative diseases.

Nearly 90% of patients with relapsing-remitting MS in a multicenter study in Germany preferred subcutaneous administration of Tysabri rather than IV, citing shorter duration of delivery and convenience, per a presentation at ECTRIMS 2022.

Preclinical biotech company Eikonoklastes Therapeutics and gene therapy manufacturer Forge Biologics announced a partnership that will advance Eikonoklastes’ ET-101 gene therapy into clinical trials for patients with ALS.